Newly marketed tissue markers for malignant mesothelioma: Immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies

Human Pathology

Volumn 28, Issue 8, 1997, Pages 929-937

  Donna, Adalberto ^b   Betta, Pier Giacomo ^a   Chiodera, Pierluigi ^b   Bellingeri, Domenico ^b   Libener, Roberta ^b   Zorzi, Fausto ^b   Tassi, Gian Franco ^b  

^a Ospedale S Spirito Casale Monferrato   (Italy)

^b NONE

Author keywords

Differential diagnosis; Immunohistochemistry; Malignant mesothelioma

Indexed keywords

CANCER ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AMAD 2; MONOCLONAL ANTIBODY HBME 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PLEURA METASTASIS; SERODIAGNOSIS;

EID: 0030841348     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90008-3     Document Type: Article

References (34)

1. Whitaker D, Shilkin KB: Diagnosis of pleural malignant mesothelioma in life: A practical approach. J Pathol 143:147-175, 1984
2. Jones JSP (ed): Pathology of the Mesothelium. London, Springer-Verlag, 1987
3. Henderson DW, Whitaker D, Shilkin KB: The differential diagnosis of malignant mesothelioma: A practical approach to diagnosis during life, in Henderson DW, Shilkin KB, Langlois SLP, et al (eds): Malignant Mesothelioma. New York, NY, Hemisphere, 1992, pp 183-197
4. Battifora H, McCaughey WTE: Tumors of the serosal membranes, in Rosai J (ed): Atlas of Tumor Pathology. (3rd series, fascicle 15). Washington, DC, Armed Forces Institute of Pathology, 1995
5. Sheibani K, Esteban JM, Bailey A, et al: Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. HUM PATHOL 23:107-116, 1992
6. Bedrossian CWM, Bonsib S, Moran C: Differential diagnosis between mesothelioma and adenocarcinoma: A multimodal approach based on ultrastructure and immunocytochemistiy. Semin Diagn Pathol 9:124-140, 1992
7. Brown RW, Clark GM, Tandon AK, et al: Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. HUM PATHOL 24:347-354, 1993
8. Leong AS-Y, Vernon-Roberts E: The immunohistochemistry of malignant mesothelioma. Pathol Annu 29(pt 2):157-179, 1994
9. Ordóñez NG, Mackay B: The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 3:273-293, 1996
10. Donna A, Betta P-G, Bellingeri D, et al: New marker for mesothelioma: An immunoperoxidase study. J Clin Pathol 39:961-968, 1986
11. Donna A, Betta P-G, Jones JSP: Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody. Cancer 63:1331-1336, 1989
12. Donna A, Betta P-G, Bellingeri D, et al: Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody. Diagn Cytopathol 8:361-365, 1992
13. Grove A, Jensen ML, Donna A: Mesothelioma of the tunica vaginalis testis and hernial sacs. Virchows Arch [A] 415:283-292, 1989
14. Monma N, Satodate R, Tashiro A, et al: Origin of the so-called mesothelioma of the atrioventricular node. Arch Pathol Lab Med 115:1026-1029, 1991
15. DAKO Corp (Carpinteria, CA): Specification sheet
16. Miettinen M, Kovatich AJ: HBME-1 a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft-tissue and bone tumors. Appl Immunohistochem 3:115-122, 1995
17. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning (ed 2). New York, NY, Cold Spring Harbor Laboratory Press, 1989
18. Andrion A, Magnani C, Betta P-G, et al: Malignant mesothelioma of the pleura: Interobserver variability. J Clin Pathol 48:856-860, 1995
19. Singh G, Whiteside TL, Dekker A: Immunodiagnosis of mesothelioma: Use of antimesothelial cell serum in an indirect immuno-fluorescence assay. Cancer 43:2288-2296, 1979
20. Anderson TM, Holmes EC, Kosaka CJ, et al: Monoclonal antibodies to human malignant mesothelioma. J Clin Immunol 7:254-261, 1987
21. Hsu S-M, Hsu P-L, Zhao X, et al: Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (Anti-MS) with diagnostic and therapeutic potential. Cancer Res 48:5228-5236, 1988
22. Stahel RA, O'Hara CJ, Waibel R, et al: Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. Int J Cancer 41:218-223, 1988
23. O'Hara CJ, Corson JM, Pinkus GS, et al: ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 136:421-428, 1990
24. Skov BG, Stahel RA, Hirsch F: ME1-antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies. Lung Cancer 11:221-227, 1994
25. Fleuren GJ, Coerkamp EG, Nap M, et al: Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas. Virchows Arch [A] 410:481-486, 1987
26. Chang K, Pai LH, Batra JK, et al: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 52:181-186, 1992
27. Delahaye M, Hoogsteden HC, van der Kwast TH: Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 165:137-143, 1991
28. Chang K, Pai LH, Pass H, et al: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16:259-268, 1992
29. Walker C, Rutten F, Yuan X, et al: Wilm's tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 54:3101-3106, 1994
30. Yamada T, Jiping J, Endo R, et al: Molecular cloning of a cell-surface glycoprotein that can potentially discriminate mesothelium from epithelium: Its identification as vascular cell adhesion molecule 1. Br J Cancer 71:562-570, 1995
31. Amin KM, Litzky LA, Smythe WR, et al: Wilm's tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-356, 1995
32. Donna A, Betta P-G, Cosimi MF, et al: Putative mesothelial cell growth-promoting activity of a cytoplasmic protein expressed by the mesothelial cell. Expl Cell Biol 57:193-197, 1989
33. Renshaw AA, Pinkus GS, Corson JM: HBME-1 aids in distinguishing mesotheliomas and adenocarcinomas of the lung and breast. Mod Pathol 8:152A, 1995 (abstr)
34. Savera AT, Raju U, Linden MD: Mesothelioma vs adenocarcinoma: Diagnostic utility of HBME-1. Lab Invest 74:162A, 1996 (abstr)